- Home
- NCLH vs ROIV Comparison
NCLH vs ROIV Comparison
Compare NCLH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCLH | ROIV |
|---|---|---|
| Founded | 1966 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 14.1B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCLH | ROIV |
|---|---|---|
| Price | $24.26 | $22.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $28.11 | $24.31 |
| AVG Volume (30 Days) | ★ 17.9M | 8.2M |
| Earning Date | 11-04-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $9,692,558,000.00 | $20,329,000.00 |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | $10.76 | $376.94 |
| P/E Ratio | $16.49 | ★ N/A |
| Revenue Growth | ★ 3.59 | N/A |
| 52 Week Low | $14.21 | $8.73 |
| 52 Week High | $29.29 | $23.47 |
Technical Indicators
Market Signals| Indicator | NCLH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 79.15 | 63.37 |
| Support Level | $21.51 | $21.60 |
| Resistance Level | $22.39 | $23.47 |
| Average True Range (ATR) | 0.82 | 0.89 |
| MACD | 0.60 | 0.07 |
| Stochastic Oscillator | 98.99 | 76.31 |
Price Performance
Historical ComparisonAbout NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.